AB 848: Medi-Cal: covered benefits: continuous glucose monitors.
- Session Year: 2019-2020
- House: Assembly
- Latest Version Date: 2019-09-11
|
Date
|
Status
|
|---|---|
| Jan 21, 2020 | Consideration of Governor's veto stricken from file. |
| Oct 13, 2019 | Vetoed by Governor. |
| Sep 13, 2019 | Enrolled and presented to the Governor at 3:30 p.m. |
| Sep 9, 2019 | Senate amendments concurred in. To Engrossing and Enrolling. (Ayes 79. Noes 0.). |
| Sep 5, 2019 | In Assembly. Concurrence in Senate amendments pending. May be considered on or after September 7 pursuant to Assembly Rule 77. |
| Sep 4, 2019 | Read third time. Passed. Ordered to the Assembly. |
| Sep 3, 2019 | Read second time. Ordered to third reading. |
| Aug 30, 2019 | From committee: Amend, and do pass as amended. (Ayes 7. Noes 0.) (August 30). |
| Jun 24, 2019 | In committee: Referred to APPR. suspense file. |
| Jun 12, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 9. Noes 0.) (June 12). Re-referred to Com. on APPR. |
| May 29, 2019 | Referred to Com. on HEALTH. |
| May 23, 2019 | In Senate. Read first time. To Com. on RLS. for assignment. |
| May 22, 2019 | Read third time. Passed. Ordered to the Senate. |
| May 20, 2019 | Read second time. Ordered to third reading. |
| May 16, 2019 | Coauthors revised. |
| Apr 24, 2019 | In committee: Set, first hearing. Referred to APPR. suspense file. |
| Mar 27, 2019 | From committee: Do pass and re-refer to Com. on APPR. (Ayes 15. Noes 0.) (March 26). Re-referred to Com. on APPR. |
| Mar 4, 2019 | Referred to Com. on HEALTH. |
| Feb 21, 2019 | From printer. May be heard in committee March 23. |
| Feb 20, 2019 | Read first time. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Sep 9, 2019 | AB 848 Gray Concurrence in Senate Amendments | Assembly Floor |
Passed |
|
| Sep 4, 2019 | Assembly 3rd Reading AB848 Gray et al. By Galgiani | Senate Floor |
Passed |
|
| Aug 30, 2019 | Do pass as amended | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 24, 2019 | Placed on suspense file | Senate Standing Committee on Appropriations |
Passed |
|
| Jun 12, 2019 | Do pass, but first be re-referred to the Committee on [Appropriations] | Senate Standing Committee on Health |
Passed |
|
| May 22, 2019 | AB 848 Gray Assembly Third Reading | Assembly Floor |
Passed |
|
| May 16, 2019 | Do pass. | Assembly Standing Committee on Appropriations |
Passed |
|
| Mar 26, 2019 | Do pass and be re-referred to the Committee on [Appropriations] | Assembly Standing Committee on Health |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
GOVERNOR'S VETO
GV Bill Id:AB 848
Author:(Gray)
As Enrolled Ver:September 11, 2019
2/3 vote
SUMMARY:
Requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies required for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization controls. Permits the Department of Health Care Services (DHCS) to require the manufacturer of a continuous glucose monitor to enter into a rebate agreement with DHCS.
The Senate Amendments:
Permit DHCS to implement, interpret, or make specific this bill by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action pursuant to the Administrative Procedure Act.
Governor's Veto Message:
This bill would add continuous glucose monitors (GCMs) and related supplies for treating diabetes as a covered Medi-Cal benefit, when medically necessary.
The goal of this bill, enhancing access to GCMs in order to help individuals better manage their diabetes, is an important one and should be considered through the annual budget process.
COMMENTS:
Monitoring of blood glucose. Managing diabetes requires checking blood glucose levels through lab tests (HbA1c periodically ordered by health care providers) and daily patient self-monitoring blood glucose (SMBG), also known as a finger stick. In addition to HbA1c lab tests and SMBG, patients and providers may also use CGMs to help manage diabetes. Three manufacturers produce federal Food and Drug Administration-approved CGMs in the United States (i.e., Abbott, Dexcom, and Medtronic). These waterproof monitors, also called continuous interstitial glucose monitors, use a thin plastic catheter inserted into the subcutaneous skin (fat layer) just under the skin of the arm, back, or trunk to measure the amount of glucose in the fluid around the cells, called interstitial fluid.
DHCS COVERAGE POLICY ON CGM. DHCS indicates CGMs are a covered benefit in the California Children's Services Program (CCS) and the Genetically Handicapped Persons Program, subject to the patient and their treating specialist meeting specified criteria outlined in DHCS policy letters. For Medi-Cal, DHCS indicates CGM are a non-covered benefit, meaning that a Medi-Cal beneficiary who is over the age of 21 can obtain one with a treatment authorization request override that indicates medical necessity. For individuals under the age of 21, DHCS indicates the beneficiary may be able to obtain a CGM under the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT), subject to prior authorization in Medi-Cal and under CCS (the medical necessity standard under EPSDT for Medi-Cal is broader for children than the adult medical necessity standard in Medi-Cal). DHCS indicates it does not have rebate contracts with CGM manufacturers.
According to the Author:
Medi-Cal's refusal to cover CGM discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian's and 43% of the state's total diabetic population. Nearly every other health plan has chosen to cover CGM, including Covered California, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in health care outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to 10 times as many diabetes-related amputations as their non-Medi-Cal counterparts.
Arguments in Support:
The American Diabetes Association (ADA) writes that it supports making CGMs a Medi-Cal covered benefit because the alarm function of these monitors alerts diabetes patients when their blood levels go dangerously high or dangerously low in a way that traditional, finger stick measurement cannot. Traditional finger stick measurement only shows a snapshot of blood glucose at that moment but does not warn of rapidly rising or falling levels, which is necessary for the patient to make informed, effective decisions in managing their disease. The ADA writes that CGMs can reduce short-term costs to the Medi-Cal program by reducing severe hypoglycemic events in high-risk populations, and most states' Medicaid program cover CGMs because they improve diabetes control and help prevent greater costs associated with hospitalizations and treatment complications.
Western Center on Law & Poverty (WCLP) writes in support that, although Medi-Cal covers all medically necessary services, including CGMs, legal aid advocates cite the need for this bill. WCLP states that advocates report cases of Medi-Cal managed care plans denying clients' request for CGM, which can result in a lengthy appeal process where the plan's decision is ultimately reversed but the client went months without the needed CGM.
Arguments in Opposition:
The Department of Finance opposes this bill because it allocates significant General Fund (GF) resources that should be considered with other General Fund priorities through the annual budget process. Explicit authorization of this benefit in statute is likely to result in a significant increase in utilization and associated costs in the Medi-Cal program. Medi-Cal currently provides coverage for diabetes screening as recommended by the United States Preventive Services Task Force Grade "A" and "B" recommendations.
FISCAL COMMENTS:
According to the Senate Appropriations Committee, according to the DHCS, annual $100.8 million Total Funds (TF) ($31.9 million GF, $68.9 million Federal Fund (FF)) the first year and $92.7 million TF ($29.4 million GF, $63.3 million FF) the second year. The first year's costs include a one-time cost for the CGM receiver, as well as monthly costs for sensors and transmitters; the second year's costs only account for the ongoing monthly cost of the transmitters and sensors. Costs may increase if the receiver equipment needs replacement. DHCS notes that costs could vary to the extent the department is able to negotiate reimbursement rates and secure rebate agreements with manufacturers. DHCS does not anticipate needing any additional staffing at this time to administer this new policy.
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ASSEMBLY FLOOR: 78-0-2
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Cooley, Eduardo Garcia
SENATE FLOOR: 40-0-0
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
ASSEMBLY FLOOR: 79-0-0
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooley, Cooper, Cunningham, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Eduardo Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
UPDATED:
VERSION: September 11, 2019
CONSULTANT: Scott Bain / HEALTH / (916) 319-2097 FN: 0002590
CONCURRENCE IN SENATE AMENDMENTS
CSA1 Bill Id:AB 848
Author:(Gray)
As Amended Ver:August 30, 2019
Majority vote
SUMMARY:
Requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies required for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization controls. Permits the Department of Health Care Services (DHCS) to require the manufacturer of a continuous glucose monitor to enter into a rebate agreement with DHCS.
The Senate Amendments:
Permit DHCS to to implement, interpret, or make specific this bill by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action pursuant to the Administrative Procedure Act.
COMMENTS:
Monitoring of blood glucose. Managing diabetes requires checking blood glucose levels through lab tests (HbA1c periodically ordered by health care providers) and daily patient self-monitoring blood glucose (SMBG), also known as a finger stick. In addition to HbA1c lab tests and SMBG, patients and providers may also use CGMs to help manage diabetes. Three manufacturers produce federal Food and Drug Administration-approved CGMs in the United States (i.e., Abbott, Dexcom, and Medtronic). These waterproof monitors, also called continuous interstitial glucose monitors, use a thin plastic catheter inserted into the subcutaneous skin (fat layer) just under the skin of the arm, back, or trunk to measure the amount of glucose in the fluid around the cells, called interstitial fluid.
THE DEPARTMENT OF HEALTH CARE SERVICES (DHCS) COVERAGE POLICY ON CGM. DHCS indicates CGMs are a covered benefit in the California Children's Services Program (CCS) and the Genetically Handicapped Persons Program, subject to the patient and their treating specialist meeting specified criteria outlined in DHCS policy letters. For Medi-Cal, DHCS indicates CGM are a non-covered benefit, meaning that a Medi-Cal beneficiary who is over the age of 21 can obtain one with a treatment authorization request override that indicates medical necessity. For individuals under the age of 21, DHCS indicates the beneficiary may be able to obtain a CGM under the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT), subject to prior authorization in Medi-Cal and under CCS (the medical necessity standard under EPSDT for Medi-Cal is broader for children than the adult medical necessity standard in Medi-Cal). DHCS indicates it does not have rebate contracts with CGM manufacturers.
According to the Author:
Medi-Cal's refusal to cover CGM discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian's and 43% of the state's total diabetic population. Nearly every other health plan has chosen to cover CGM, including Covered California, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in health care outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to 10 times as many diabetes-related amputations as their non-Medi-Cal counterparts.
Arguments in Support:
The American Diabetes Association (ADA) writes that it supports making CGMs a Medi-Cal covered benefit because the alarm function of these monitors alerts diabetes patients when their blood levels go dangerously high or dangerously low in a way that traditional, finger stick measurement cannot. Traditional finger stick measurement only shows a snapshot of blood glucose at that moment but does not warn of rapidly rising or falling levels, which is necessary for the patient to make informed, effective decisions in managing their disease. The ADA writes that CGMs can reduce short-term costs to the Medi-Cal program by reducing severe hypoglycemic events in high-risk populations, and most states' Medicaid program cover CGMs because they improve diabetes control and help prevent greater costs associated with hospitalizations and treatment complications.
Western Center on Law & Poverty (WCLP) writes in support that, although Medi-Cal covers all medically necessary services, including CGMs, legal aid advocates cite the need for this bill. WCLP states that advocates report cases of Medi-Cal managed care plans denying clients' request for CGM, which can result in a lengthy appeal process where the plan's decision is ultimately reversed but the client went months without the needed CGM.
Arguments in Opposition:
The Department of Finance opposes this bill because it allocates significant General Fund (GF) resources that should be considered with other General Fund priorities through the annual budget process. Explicit authorization of this benefit in statute is likely to result in a significant increase in utilization and associated costs in the Medi-Cal program. Medi-Cal currently provides coverage for diabetes screening as recommended by the United States Preventive Services Task Force Grade "A" and "B" recommendations.
FISCAL COMMENTS:
According to the Senate Appropriations Committee, according to the DHCS, annual $100.8 million Total Funds (TF) ($31.9 million GF, $68.9 million Federal Fund (FF)) the first year and $92.7 million TF ($29.4 million GF, $63.3 million FF) the second year. The first year’s costs include a one-time cost for the CGM receiver, as well as monthly costs for sensors and transmitters; the second year’s costs only account for the ongoing monthly cost of the transmitters and sensors. Costs may increase if the receiver equipment needs replacement. DHCS notes that costs could vary to the extent the department is able to negotiate reimbursement rates and secure rebate agreements with manufacturers. DHCS does not anticipate needing any additional staffing at this time to administer this new policy.
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
ASSEMBLY FLOOR: 78-0-2
YES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, O'Donnell, Obernolte, Patterson, Petrie‑Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
ABS, ABST OR NV: Cooley, Eduardo Garcia
SENATE FLOOR: 40-0-0
YES: Allen, Archuleta, Atkins, Bates, Beall, Borgeas, Bradford, Caballero, Chang, Dahle, Dodd, Durazo, Galgiani, Glazer, Lena Gonzalez, Grove, Hertzberg, Hill, Hueso, Hurtado, Jackson, Jones, Leyva, McGuire, Mitchell, Monning, Moorlach, Morrell, Nielsen, Pan, Portantino, Roth, Rubio, Skinner, Stern, Stone, Umberg, Wieckowski, Wiener, Wilk
UPDATED:
VERSION: August 30, 2019
CONSULTANT: Scott Bain / HEALTH / (916) 319-2097 FN: 0002004
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | AB 848 |
THIRD READING
Bill No: AB 848
Amended: 8/30/19 in Senate
SENATE HEALTH COMMITTEE: 9-0, 6/12/19
AYES: Pan, Stone, Durazo, Grove, Hurtado, Leyva, Mitchell, Monning, Rubio
SENATE APPROPRIATIONS COMMITTEE: 7-0, 8/30/19
AYES: Portantino, Bates, Bradford, Durazo, Hill, Jones, Wieckowski
ASSEMBLY FLOOR: 78-0, 5/22/19 - See last page for vote
SUBJECT: Medi-Cal: covered benefits: continuous glucose monitors
DIGEST:
This bill requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization control.
Existing law:
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which low-income individuals are eligible for medical coverage. [WIC §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes, subject to utilization controls, diabetic testing supplies when covered by a pharmacy and durable medical equipment and medical supplies. [WIC §14132]
This bill:
- Requires Medi-Cal to provide coverage for CGMs and related supplies for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization control.
- Authorizes DHCS to require CGM manufacturers to enter into a rebate agreement with DHCS.
- Requires this bill to be implemented only to the extent that FFP is available and any necessary federal approvals have been obtained.
- Authorizes DHCS to implement, interpret, or make specific this bill by means of all-county letters, plan letters, plan or provider bulletins, or similar instructions, without taking any further regulatory action.
Comments
- Author’s statement. According to the author, Medi-Cal’s refusal to cover continuous glucose monitors discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian’s and 43% of the state’s total diabetic population. Nearly every other health plan has chosen to cover continuous glucose monitors, including Covered CA, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in healthcare outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to ten times as many diabetes-related amputations as their non-Medi-Cal counterparts.
- Diabetes mellitus. Diabetes mellitus is a chronic health condition that prevents the proper production of or response to insulin, which affects the body’s ability to turn food into energy. According to the Centers for Disease Control and Prevention (CDC), there are three main types of diabetes:
- Type 1 diabetes. Type 1 diabetes is thought to be caused by an autoimmune reaction the prevents the body from making insulin. About 5% of the people who have diabetes have type 1. Symptoms of type 1 diabetes often develop quickly. It is usually diagnosed in children, teens, and young adults. Individuals with type 1 diabetes require daily, lifetime use of insulin and dietary modifications.
- Type 2 diabetes. With type 2 diabetes, the body does not properly respond to insulin and, in some cases, does not produce enough insulin. About 90% of people with diabetes have type 2. Type 2 diabetes develops over many years and is usually diagnosed in adults, though it is increasingly being diagnosed in in children, teens, and young adults. Treatments include diet modification, exercise, weight loss, oral medication, and insulin.
- Gestational diabetes. Gestational diabetes develops in pregnant women and is generally diagnose in the second trimester. For most, the condition resolves after delivery but women who had it may be at risk for type 2 diabetes later in life. Treatments include diet modification, exercise, medication, and insulin.
- CGM. Monitoring blood glucose level is a key part of managing diabetes. This is done through lab tests performed periodically through health care providers and daily patient self-monitoring. CGMs are a type of blood glucose monitor for diabetics, which attaches to the patients skin, usually, the arm, back, or trunk of the body, and measures glucose in the fluid around the cells in the layer of fat just under the skin. CGMs also include a transmitter, which sits on top of the sensor and sends glucose levels to a receiver, which collects and tracks data.
CGMs may be categorized as retrospective or in real time based on how often and by whom the glucose level readings are reviewed. Under the retrospective scenario, a health care provider asks the patient to wear the CGM for 72 hours to record glucose measurements every five to 15 minutes for the duration. The patient does not see the CGM glucose levels while wearing the device. The patient returns to the provider who downloads and analyzes the retrospective data for patterns in glucose control. The provider can use this retrospective data to understand why a patient’s blood glucose remains uncontrolled even if self-monitoring blood glucose (SMBG) results appear controlled. This detailed information can be used to inform the patient’s treatment regimen including changes to insulin, other medications, and diet that are meant to improve diabetes control and subsequent long-term diabetes outcomes. Under the real-time use scenario, CGMs are worn by the patient to actively and consistently monitor glucose throughout the day and night. The patients are able to see the CGM glucose levels on their receivers, such as a smart phone, as the measurements are taken throughout the day and night. They also have the option to set an alarm to alert them when glucose levels go too high or too low.
The U. S. Food and Drug Administration (FDA) has approved a number of CGM systems for use in children and adults to monitor real-time glucose levels, including a limited number of models for use in children as young as two years old. Users of some CGM systems still are required to do SMBG finger sticks for CGM calibration and to confirm blood glucose values prior to insulin dosing. Other CGM systems have received FDA approval to allow for replacement of SMBG finger sticks prior to making a diabetes treatment decision. These systems are classified by Center for Medicare and Medicaid as “therapeutic” CGMs and also may be integrated with other devices, such as automatic insulin dosing systems.
- Coverage policy for CGMs. While CGMs are generally not a covered benefit in Medi-Cal, beneficiaries may obtain a CGM under certain circumstances and other programs under DHCS. According to DHCS, if a Medi-Cal beneficiary over the age of 21 needs a CGM, the beneficiary must obtain a Treatment Authorization Request (TAR) that overrides CGMs as a non-covered benefit and indicate the medical necessity in order to receive coverage for it. If a Medi-Cal beneficiary is under the age of 21, CGMs may be covered as part of early, periodic screening, diagnostic, and treatment (EPSDT) services and are subject to prior authorization. California Children’s Services (CCS) and Genetically Handicapped Persons Program (GHPP) also cover CGMs so long as beneficiary meets certain requirements.
- California Health Benefits Review Program (CHBRP). AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP provided an analysis of a previous version of AB 447 (Gray of 2017), which was similar to this bill. The analysis found the following:
- Benefit coverage. CHBRP estimates requiring coverage for CGMs would affect the health insurance of 10.8 million beneficiaries in Medi-Cal, including fee-for-service (FFS), managed care, and County Organized Health Systems (COHS). Approximately 91% of beneficiaries enrolled in Medi-Cal managed care and COHS and 0% of those receiving benefits through the FFS program have coverage for CGMs.
- Utilization. Utilization of CGMs is expected to increase from 3.979 per 1,000 Medi-Cal beneficiaries to 4.386 per 1,000 Med-Cal beneficiaries.
- Medical effectiveness. Evidence of effectiveness of CGMs is strongest for real-time use by type 1 diabetes patients, which shows clear and convincing evidence of improved glycemic control (HbA1c). Overall, there is limited evidence that use of real-time CGMs for patients with type 1 diabetes are effective. A preponderance of evidence found the use of retrospective CGMs for patients with type 1 diabetes are not effective. There is limited evidence that retrospective and real-time use of CGMs are not effective for patients with type 2 diabetes. Evidence is limited for retrospective CGM and insufficient for real-time CGM for improving glucose levels or maternal pregnancy or infant health outcomes for women with gestational diabetes mellitus.
Related/Prior Legislation
AB 447 (Gray of 2017) was identical to this bill. Governor Brown vetoed AB 447. In a veto message combined with another bill, he stated that DHCS has considerable administrative authority to make changes to benefits based upon new medical evidence and clinical guidelines, and that these statutory changes are unnecessary.
FISCAL EFFECT: Appropriation: No Fiscal Com.: Yes Local: No
According to the Senate Appropriations Committee:
- According to the DHCS, annual $100.8 million Total Funds (TF) ($31.9 million General Fund (GF), $68.9 million Federal Fund (FF)) the first year and $92.7 million TF ($29.4 million GF, $63.3 million FF) the second year. The first year’s costs include a one-time cost for the CGM receiver, as well as monthly costs for sensors and transmitters; the second year’s costs only account for the ongoing monthly cost of the transmitters and sensors. Costs may increase if the receiver equipment needs replacement. DHCS notes that costs could vary to the extent the department is able to negotiate reimbursement rates and secure rebate agreements with manufacturers. DHCS does not anticipate needing any additional staffing at this time to administer this new policy.
Advanced Medical Technology Association
American Diabetes Association
American College of Obstetricians and Gynecologists District IX
Biocom
California Academy of Family Physicians
California Academy of Nutrition and Dietetics
California Association of Health Services at Home
California Chapter of the Association of Clinical Endocrinologists
California Chronic Care Coalition
CA Coordinating Body of the American Association of Diabetes Educators
California Life Sciences Association
California Optometric Association
California School Employees Association
Children’s Specialty Care Coalition
County Health Executives Association of California
Dexcom
Diabetes Patient Advocacy Coalition
Western Center on Law and Poverty
OPPOSITION: (Verified 8/26/19)
Department of Finance
ARGUMENTS IN SUPPORT: The American Diabetes Association, American Association of Diabetes Educators, California Chapter for the American Association of Clinical Endocrinologists, Diabetes Patient Advocacy Coalition write in support in a joint coalition letter. The coalition letter states that real-time CGMs can alert patients when their blood glucose levels are exceeding or falling below specified threshold. They argue that that while CGMs are covered for patients in CCS, patients who are well managed and in control will lose access once they transition to Medi-Cal as adults, leading to poorer outcomes and higher costs. This bill is also supported by Dexcom, which manufactures CGM devices, and states that this bill will provide a tremendous benefit to patients with diabetes and their caregivers.
ARGUMENTS IN OPPOSITION: The Department of Finance (DOF) is opposed to this bill because it would result in significant increases in utilization and associated costs in the Medi-Cal program. DOF argues the CGM benefit should be considered with other General Fund priorities through the annual budget process.
ASSEMBLY FLOOR: 78-0, 5/22/19
AYES: Aguiar-Curry, Arambula, Bauer-Kahan, Berman, Bigelow, Bloom, Boerner Horvath, Bonta, Brough, Burke, Calderon, Carrillo, Cervantes, Chau, Chen, Chiu, Choi, Chu, Cooper, Cunningham, Dahle, Daly, Diep, Eggman, Flora, Fong, Frazier, Friedman, Gabriel, Gallagher, Cristina Garcia, Gipson, Gloria, Gonzalez, Gray, Grayson, Holden, Irwin, Jones-Sawyer, Kalra, Kamlager-Dove, Kiley, Lackey, Levine, Limón, Low, Maienschein, Mathis, Mayes, McCarty, Medina, Melendez, Mullin, Muratsuchi, Nazarian, Obernolte, O'Donnell, Patterson, Petrie-Norris, Quirk, Quirk-Silva, Ramos, Reyes, Luz Rivas, Robert Rivas, Rodriguez, Blanca Rubio, Salas, Santiago, Smith, Mark Stone, Ting, Voepel, Waldron, Weber, Wicks, Wood, Rendon
NO VOTE RECORDED: Cooley, Eduardo Garcia
Prepared by: Kimberly Chen / HEALTH / (916) 651-4111
9/3/19 8:55:29
**** END ****
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 848 (Gray) - Medi-Cal: covered benefits: continuous glucose monitors
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
Assembly Bill 848 would add continuous glucose monitors (CGMs) and related supplies required for their use for the treatment of diabetes mellitus (diabetes) to the schedule of covered Medi-Cal benefits, when medically necessary. Would re-affirm the Department of Health Care Services (DHCS)’s authority to require a CGM manufacturer to enter into a rebate agreement. Coverage would be subject to utilization controls, federal financial participation (FFP), and federal approval.
*********** ANALYSIS ADDENDUM – SUSPENSE FILE ***********
The following information is revised to reflect amendments
adopted by the committee on August 30, 2019
Fiscal Impact:
According to the DHCS, annual $100.8 million Total Funds (TF) ($31.9 million General Fund (GF), $68.9 million Federal Fund (FF)) the first year and $92.7 million TF ($29.4 million GF, $63.3 million FF) the second year. The first year’s costs include a one-time cost for the CGM receiver, as well as monthly costs for sensors and transmitters; the second year’s costs only account for the ongoing monthly cost of the transmitters and sensors. Costs may increase if the receiver equipment needs replacement. DHCS notes that costs could vary to the extent the department is able to negotiate reimbursement rates and secure rebate agreements with manufacturers. DHCS does not anticipate needing any additional staffing at this time to administer this new policy.
Author Amendments:
The author’s amendments would require DHCS to cover continuous glucose monitors and supplies and would clarify the department can implement the bill’s provisions through all-county letters, plan letters, plan or provider bulletins, without taking regulatory action.
-- END --
SENATE COMMITTEE ON
Senator Anthony Portantino, Chair
2019 - 2020 Regular Session
AB 848 (Gray) - Medi-Cal: covered benefits: continuous glucose monitors
Version: | Policy Vote: |
Urgency: | Mandate: |
Hearing Date: | Consultant: |
Bill Summary:
Assembly Bill 848 would add continuous glucose monitors (CGMs) and related supplies required for their use for the treatment of diabetes mellitus (diabetes) to the schedule of covered Medi-Cal benefits, when medically necessary. Would re-affirm the Department of Health Care Services (DHCS)’s authority to require a CGM manufacturer to enter into a rebate agreement. Coverage would be subject to utilization controls, federal financial participation (FFP), and federal approval.
Fiscal Impact:
According to the DHCS, annual $100.8 million Total Funds (TF) ($31.9 million General Fund (GF), $68.9 million Federal Fund (FF)) the first year and $92.7 million TF ($29.4 million GF, $63.3 million FF) the second year. The first year’s costs include a one-time cost for the CGM receiver, as well as monthly costs for sensors and transmitters; the second year’s costs only account for the ongoing monthly cost of the transmitters and sensors. Costs may increase if the receiver equipment needs replacement. DHCS notes that costs could vary to the extent the department is able to negotiate reimbursement rates and secure rebate agreements with manufacturers. DHCS does not anticipate needing any additional staffing at this time to administer this new policy.
Background:
Under state and federal law, the Department of Health Care Services operates the Medi-Cal program, which provides health care coverage to low income individuals, families, and children. Medi-Cal provides coverage to childless adults and parents with household incomes up to 138% of the federal poverty level and to children with household incomes up to 266% of the federal poverty level. The federal government provides matching funds that vary from 50% to 90% of expenditures depending on the category of beneficiary.
Continuous glucose monitors allow patients with diabetes to better track their blood glucose levels. For some patients, when blood glucose levels are poorly controlled, there can be adverse health events leading to hospitalization. Short-term instances of either very high blood glucose levels (hyperglycemia) or very low blood glucose levels (hypoglycemia) can result in a variety of short-term impacts that may necessitate hospitalization. In addition, there are a number of serious health impacts associated with long-term poorly controlled blood glucose levels.
CGMs are a type of blood glucose monitor, which includes a transmitter that sits on top of the sensor and sends glucose levels to a receiver, which collects and tracks data. According to the Senate Health Committee analysis of this bill, while CGMs are generally not a covered benefit in Medi-Cal, beneficiaries may obtain a CGM under certain circumstances and other programs under DHCS. For example, if a Medi-Cal beneficiary over the age of 21 needs a CGM, the beneficiary must obtain a Treatment Authorization Request (TAR) that overrides CGMs as a non-covered benefit and indicate the medical necessity in order to receive coverage for it. If a Medi-Cal beneficiary is under the age of 21, CGMs may be covered as part of early, periodic screening, diagnostic, and treatment (EPSDT) services and are subject to prior authorization. California Children’s Services (CCS) and Genetically Handicapped Persons Program (GHPP) also cover CGMs so long as beneficiary meets certain requirements.
Proposed Law:
AB 848 includes the following provisions:
- Requires CGMs and related supplies required for use with those monitors are covered for diabetes treatment when medically necessary, subject to utilization controls.
- Authorizes the DCHS to require the manufacturer of a continuous glucose monitor to enter into a rebate agreement with the department.
- Conditions implementation only to the extent that federal financial participation is available and any necessary federal approvals have been obtained.
Related Legislation:
- AB 447 (Gray, 2017) was identical to this bill. Governor Brown vetoed AB 447 in a veto message citing, “DHCS has considerable administrative authority to make changes to benefits based upon new medical evidence and clinical guidelines, and that these statutory changes are unnecessary.”
Staff Comments:
The DHCS identifies the Medi-Cal population with diabetes to be 1,065,503 beneficiaries. Of this population, an estimated 38,871 adult Medi-Cal beneficiaries would utilize CGMs. The fiscal estimate does not exclude costs for individuals who are over age 21 and may already be approved for and using CGMs. However, because there are very few approved adult users, DHCS assumes these costs are relatively low.
Higher utilization of CGMs could produce long-term cost avoidance through improved diabetes management, fewer emergency rooms visits, etc. Similarly, support costs could also increase due to the increased access to, and thus demand for, DME, supplies, and accessories. However, these potential cost avoidances and cost increases are not estimable at this time.
-- END --
SENATE COMMITTEE ON HEALTH
Senator Dr. Richard Pan, Chair
BILL NO: AB 848
AUTHOR: | Gray | ||
VERSION: | February 20, 2019 | ||
HEARING DATE: | June 12, 2019 | ||
CONSULTANT: | Kimberly Chen | ||
SUBJECT: Medi-Cal: covered benefits: continuous glucose monitors
SUMMARY:
Requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization control.
Existing law:
- Establishes the Medi-Cal program, administered by the Department of Health Care Services (DHCS), under which low-income individuals are eligible for medical coverage. [WIC §14000, et seq.]
- Establishes a schedule of benefits under the Medi-Cal program, which includes, subject to utilization controls, diabetic testing supplies when covered by a pharmacy and durable medical equipment and medical supplies. [WIC §14132]
This bill:
- Requires Medi-Cal to provide coverage for continuous glucose monitors and related supplies for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization control.
- Authorizes DHCS to require continuous glucose monitor manufacturers to enter into a rebate agreement with DHCS.
- Requires this bill to be implemented only to the extent that FFP is available and any necessary federal approvals have been obtained.
FISCAL EFFECT:
According to the Assembly Appropriations Committee:
- Additional costs in fee-for-service Medi-Cal and cost pressure to Medi-Cal managed care cost pressure in the millions annually (General Fund (GF)/federal). Most Medi-Cal managed care enrollees already have coverage for CGMs. Costs would depend on the price of current and new devices, utilization and the utilization controls imposed by DHCS.
- Minor and absorbable administrative costs to Department of Health Care Services to update relevant provider manuals, codes and contacts to add CGMs as a covered benefit (GF/federal).
PRIOR VOTES:
Assembly Floor: | 78 - 0 |
Assembly Appropriations Committee: | 18 - 0 |
Assembly Health Committee: | 15 - 0 |
COMMENTS:
- Author’s statement. According to the author, Medi-Cal’s refusal to cover continuous glucose monitors discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian’s and 43% of the state’s total diabetic population. Nearly every other health plan has chosen to cover continuous glucose monitors, including Covered CA, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in healthcare outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to ten times as many diabetes-related amputations as their non-Medi-Cal counterparts.
- Diabetes mellitus. Diabetes mellitus is a chronic health condition that prevents the proper production of or response to insulin, which affects the body’s ability to turn food into energy. According to the Centers for Disease Control and Prevention (CDC), there are three main types of diabetes:
- Type 1 diabetes. Type 1 diabetes is thought to be caused by an autoimmune reaction the prevents the body from making insulin. About 5% of the people who have diabetes have type 1. Symptoms of type 1 diabetes often develop quickly. It is usually diagnosed in children, teens, and young adults. Individuals with type 1 diabetes require daily, lifetime use of insulin and dietary modifications.
- Type 2 diabetes. With type 2 diabetes, the body does not properly respond to insulin and, in some cases, does not produce enough insulin. About 90% of people with diabetes have type 2. Type 2 diabetes develops over many years and is usually diagnosed in adults, though it is increasingly being diagnosed in in children, teens, and young adults. Treatments include diet modification, exercise, weight loss, oral medication, and insulin.
- Gestational diabetes. Gestational diabetes develops in pregnant women and is generally diagnose in the second trimester. For most, the condition resolves after delivery but women who had it may be at risk for type 2 diabetes later in life. Treatments include diet modification, exercise, medication, and insulin.
- CGM. Monitoring blood glucose level is a key part of managing diabetes. This is done through lab tests performed periodically through health care providers and daily patient self-monitoring. CGMs are a type of blood glucose monitor for diabetics, which attaches to the patients skin, usually, the arm, back, or trunk of the body, and measures glucose in the fluid around the cells in the layer of fat just under the skin. CGMs also include a transmitter, which sits on top of the sensor and sends glucose levels to a receiver, which collects and tracks data.
CGMs may be categorized as retrospective or in real time based on how often and by whom the glucose level readings are reviewed. Under the retrospective scenario, a health care provider asks the patient to wear the CGM for 72 hours to record glucose measurements every five to 15 minutes for the duration. The patient does not see the CGM glucose levels while wearing the device. The patient returns to the provider who downloads and analyzes the retrospective data for patterns in glucose control. The provider can use this retrospective data to understand why a patient’s blood glucose remains uncontrolled even if self-monitoring blood glucose (SMBG) results appear controlled. This detailed information can be used to inform the patient’s treatment regimen including changes to insulin, other medications, and diet that are meant to improve diabetes control and subsequent long-term diabetes outcomes. Under the real-time use scenario, CGMs are worn by the patient to actively and consistently monitor glucose throughout the day and night. The patients are able to see the CGM glucose levels on their receivers, such as a smart phone, as the measurements are taken throughout the day and night. They also have the option to set an alarm to alert them when glucose levels go too high or too low.
The U. S. Food and Drug Administration (FDA) has approved a number of CGM systems for use in children and adults to monitor real-time glucose levels, including a limited number of models for use in children as young as two years old. Users of some CGM systems still are required to do SMBG finger sticks for CGM calibration and to confirm blood glucose values prior to insulin dosing. Other CGM systems have received FDA approval to allow for replacement of SMBG finger sticks prior to making a diabetes treatment decision. These systems are classified by Center for Medicare and Medicaid as “therapeutic” CGMs and also may be integrated with other devices, such as automatic insulin dosing systems.
- Coverage policy for CGMs. While CGMs are generally not a covered benefit in Medi-Cal, beneficiaries may obtain a CGM under certain circumstances and other programs under DHCS. According to DHCS, if a Medi-Cal beneficiary over the age of 21 needs a CGM, the beneficiary must obtain a Treatment Authorization Request (TAR) that overrides CGMs as a non-covered benefit and indicate the medical necessity in order to receive coverage for it. If a Medi-Cal beneficiary is under the age of 21, CGMs may be covered as part of early, periodic screening, diagnostic, and treatment (EPSDT) services and are subject to prior authorization. California Children’s Services (CCS) and Genetically Handicapped Persons Program (GHPP) also cover CGMs so long as beneficiary meets certain requirements.
- California Health Benefits Review Program (CHBRP). AB 1996 (Thomson, Chapter 795, Statutes of 2002) requests the University of California to assess legislation proposing a mandated benefit or service and prepare a written analysis with relevant data on the medical, economic, and public health impacts of proposed health plan and health insurance benefit mandate legislation. CHBRP provided an analysis of a previous version of AB 447 (Gray of 2017), which was similar to this bill. The analysis found the following:
- Benefit coverage. CHBRP estimates requiring coverage for CGMs would affect the health insurance of 10.8 million beneficiaries in Medi-Cal, including fee-for-service (FFS), managed care, and County Organized Health Systems (COHS). Approximately 91% of beneficiaries enrolled in Medi-Cal managed care and COHS and 0% of those receiving benefits through the FFS program have coverage for CGMs.
- Utilization. Utilization of CGMs is expected to increase from 3.979 per 1,000 Medi-Cal beneficiaries to 4.386 per 1,000 Med-Cal beneficiaries.
- Medical effectiveness. Evidence of effectiveness of CGMs is strongest for real-time use by type 1 diabetes patients, which shows clear and convincing evidence of improved glycemic control (HbA1c). Overall, there is limited evidence that use of real-time CGMs for patients with type 1 diabetes are effective. A preponderance of evidence found the use of retrospective CGMs for patients with type 1 diabetes are not effective. There is limited evidence that retrospective and real-time use of CGMs are not effective for patients with type 2 diabetes. Evidence is limited for retrospective CGM and insufficient for real-time CGM for improving glucose levels or maternal pregnancy or infant health outcomes for women with gestational diabetes mellitus.
- Prior legislation. AB 447 (Gray of 2017) was identical to this bill. Governor Brown vetoed AB 447 in a veto message combined with another bill, stating DHCS has considerable administrative authority to make changes to benefits based upon new medical evidence and clinical guidelines, and that these statutory changes are unnecessary.
- Support. The American Diabetes Association, American Association of Diabetes Educators, California Chapter for the American Association of Clinical Endocrinologists, Diabetes Patient Advocacy Coalition write in support in a joint coalition letter. The coalition letter states that real-time CGMs can alert patients when their blood glucose levels are exceeding or falling below specified threshold. They argue that that while CGMs are covered for patients in CCS, patients who are well managed and in control will lose access once they transition to Medi-Cal as adults, leading to poorer outcomes and higher costs. This bill is also supported by Dexcom, which manufactures CGM devices, and states that this bill will provide a tremendous benefit to patients with diabetes and their caregivers.
SUPPORT AND OPPOSITION:
Support: Advanced Medical Technology Association
American Diabetes Association
American College of Obstetricians and Gynecologists District IX
Biocom
California Academy of Family Physicians
California Academy of Nutrition and Dietetics
California Association of Health Services at Home
California Chapter of the Association of Clinical Endocrinologists
California Chronic Care Coalition
CA Coordinating Body of the American Association of Diabetes Educators
California Life Sciences Association
California Optometric Association
California School Employees Association
Children’s Specialty Care Coalition
County Health Executives Association of California
Dexcom
Diabetes Patient Advocacy Coalition
Western Center on Law and Poverty
Oppose: None received
-- END --
ASSEMBLY THIRD READING
ATR Bill Id:AB 848
Author:(Gray)
As Introduced Ver:February 20, 2019
Majority vote
SUMMARY:
Requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies required for use with those monitors for the treatment of diabetes mellitus when medically necessary, subject to utilization controls.
Major Provisions
COMMENTS:
Monitoring of blood glucose. Managing diabetes requires checking blood glucose levels through lab tests (HbA1c periodically ordered by health care providers) and daily patient self-monitoring blood glucose (SMBG), also known as a finger stick. In addition to HbA1c lab tests and SMBG, patients and providers may also use CGMs to help manage diabetes. Three manufacturers produce federal Food and Drug Administration-approved CGMs in the U.S. (i.e., Abbott, Dexcom, and Medtronic). These waterproof monitors, also called continuous interstitial glucose monitors, use a thin plastic catheter inserted into the subcutaneous skin (fat layer) just under the skin of the arm, back, or trunk to measure the amount of glucose in the fluid around the cells, called interstitial fluid.
THE DEPARTMENT OF HEALTH CARE SERVICES (DHCS) COVERAGE POLICY ON CGM. DHCS indicates CGMs are a covered benefit in the California Children's Services Program (CCS) and the Genetically Handicapped Persons Program, subject to the patient and their treating specialist meeting specified criteria outlined in DHCS policy letters. For Medi-Cal, DHCS indicates CGM are a non-covered benefit, meaning that a Medi-Cal beneficiary who is over the age of 21 can obtain one with a treatment authorization request override that indicates medical necessity. For individuals under the age of 21, DHCS indicates the beneficiary may be able to obtain a CGM under the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT), subject to prior authorization in Medi-Cal and under CCS (the medical necessity standard under EPSDT for Medi-Cal is broader for children than the adult medical necessity standard in Medi-Cal). DHCS indicates it does not have rebate contracts with CGM manufacturers.
According to the Author:
Medi-Cal's refusal to cover CGM discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian's and 43% of the state's total diabetic population. Nearly every other health plan has chosen to cover CGM, including Covered California, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in health care outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to 10 times as many diabetes-related amputations as their non-Medi-Cal counterparts.
Arguments in Support:
The American Diabetes Association (ADA) writes that it supports making CGMs a Medi-Cal covered benefit because the alarm function of these monitors alerts diabetes patients when their blood levels go dangerously high or dangerously low in a way that traditional, finger stick measurement cannot. Traditional finger stick measurement only shows a snapshot of blood glucose at that moment but does not warn of rapidly rising or falling levels, which is necessary for the patient to make informed, effective decisions in managing their disease. The ADA writes that CGMs can reduce short-term costs to the Medi-Cal program by reducing severe hypoglycemic events in high-risk populations, and most states' Medicaid program cover CGMs because they improve diabetes control and help prevent greater costs associated with hospitalizations and treatment complications.
Western Center on Law & Poverty (WCLP) writes in support that, although Medi-Cal covers all medically necessary services, including CGMs, legal aid advocates cite the need for this bill. WCLP states that advocates report cases of Medi-Cal managed care plans denying clients' request for CGM, which can result in a lengthy appeal process where the plan's decision is ultimately reversed but the client went months without the needed CGM.
Arguments in Opposition:
There is no known opposition.
FISCAL COMMENTS:
According to the Assembly Appropriations Committee:
- Additional costs in fee-for-service Medi-Cal and cost pressure to Medi-Cal managed care cost pressure in the millions annually (General Fund (GF)/federal). Most Medi-Cal managed care enrollees already have coverage for CGMs. Costs would depend on the price of current and new devices, utilization and the utilization controls imposed by DHCS.
- Minor and absorbable administrative costs to Department of Health Care Services to update relevant provider manuals, codes and contacts to add CMGs as a covered benefit (GF/federal).
VOTES:
ASM HEALTH: 15-0-0
YES: Wood, Mayes, Aguiar-Curry, Bigelow, Bonta, Burke, Carrillo, Flora, Limón, McCarty, Nazarian, Ramos, Rodriguez, Santiago, Waldron
ASM APPROPRIATIONS: 18-0-0
YES: Gonzalez, Bigelow, Bloom, Bonta, Brough, Calderon, Carrillo, Chau, Diep, Eggman, Fong, Gabriel, Eduardo Garcia, Maienschein, Obernolte, Petrie-Norris, Quirk, Robert Rivas
UPDATED:
VERSION: February 20, 2019
CONSULTANT: Scott Bain / HEALTH / (916) 319-2097 FN: 0000658
Date of Hearing: April 24, 2019
ASSEMBLY COMMITTEE ON APPROPRIATIONS
Lorena Gonzalez, Chair
ABPCA Bill Id:AB 848
Author:(Gray) – As Introduced Ver:February 20, 2019
Policy Committee: | Health | Vote: | 15 - 0 |
Urgency: No State Mandated Local Program: No Reimbursable: No
SUMMARY:
This bill requires coverage for continuous glucose monitors (CGMs) in the Medi-Cal program for the treatment of diabetes mellitus when medically necessary, subject to utilization controls.
It also specifies it may require the manufacturer of a continuous glucose monitor to enter into a rebate agreement with the department and makes implementation of the benefit contingent on federal financial participation and necessary federal approvals.
FISCAL EFFECT:
- Additional costs in fee-for-service (FFS) Medi-Cal and cost pressure to Medi-Cal managed care cost pressure in the millions annually (GF/federal). Most Medi-Cal managed care enrollees already have coverage for CGMs. Costs would depend on the price of current and new devices, utilization and the utilization controls imposed by DHCS.
- Minor and absorbable administrative costs to Department of Health Care Services to update relevant provider manuals, codes and contacts to add CMGs as a covered benefit (GF/federal).
COMMENTS:
- Purpose. This bill adds CGMs as a Medi-Cal covered benefit to align Medi-Cal with most commercial payers and ensure vulnerable patients who need these devices can access them.
- Background. Diabetes requires regular monitoring of glucose levels. The most common method is fingerstick testing, in which a small drop of blood is taken from the finger and placed on a test strip, which is measured by a handheld device called a glucometer. According to the National Institutes of Health, CGM systems, instead, use a tiny sensor inserted under the skin to check glucose levels in tissue fluid. The sensor stays in place for several days to a week and then must be replaced. A transmitter sends information about glucose levels via radio waves from the sensor to a pagerlike wireless monitor. The monitors are more expensive than traditional "fingerstick" blood glucose tests and are not yet as widely used.
- CHBRP Report. CHBRP reports, CGMs are strongest for real-time use by Type 1 diabetes patients, which shows clear and convincing evidence of improved glycemic control (with consistent CGM adherence). With respect to Type 2 diabetes, CHBRP reports limited evidence that real-time use of CGMs are not effective for patients with type 2 diabetes, and no evidence of effectiveness.
- Prior Legislation. AB 447 (Gray), of the 2017-18 Legislative Session, was similar to this bills and was vetoed by Governor Brown, who noted DHCS has considerable administrative authority to make changes to benefits based upon new medical evidence and clinical guidelines, rendering statutory changes are unnecessary.
Analysis Prepared by: Lisa Murawski / APPR. / (916) 319-2081
Date of Hearing: March 26, 2019
ASSEMBLY COMMITTEE ON HEALTH
Jim Wood, Chair
ABPCA Bill Id:AB 848 (
Author:Gray) – As Introduced Ver:February 20, 2019
SUBJECT: Medi-Cal: covered benefits: continuous glucose monitors.
SUMMARY: Requires Medi-Cal to provide coverage for continuous glucose monitors (CGM) and related supplies required for use with those monitors for the treatment of diabetes mellitus (DM) when medically necessary, subject to utilization controls. Specifically, this bill:
- Requires Medi-Cal to provide coverage for CGM and related supplies required for use with those monitors are covered for the treatment of DM when medically necessary, subject to utilization controls.
- Permits the Department of Health Care Services (DHCS) to require the manufacturer of a CGM to enter into a rebate agreement with DHCS.
- Implements this bill only to the extent that federal financial participation (FFP) is available and any necessary federal approvals have been obtained.
EXISTING LAW:
- Establishes the Medi-Cal program, administered by DHCS, under which health care services are provided to qualified low-income persons.
- Establishes a schedule of benefits in Medi-Cal, which includes the following:
- Durable medical equipment and medical supplies, subject to utilization controls;
- Therapeutic shoes and inserts when provided to beneficiaries with a diagnosis of diabetes, subject to utilization controls, to the extent that FFP is available; and,
- Diabetic testing supplies when provided by a pharmacy, subject to utilization controls.
- Prohibits Medi-Cal payment for diabetic testing supplies from exceeding the estimated acquisition cost of the item dispensed, as defined by DHCS, plus a fee equal to the maximum professional fee component used in the payment for legend generic drug types.
FISCAL EFFECT: This bill has not been analyzed by a fiscal committee.
COMMENTS:
- PURPOSE OF THIS BILL. According to the author, Medi-Cal’s refusal to cover CGM discriminates against people of color and the poor who are more likely to be diagnosed with diabetes and experience complications from this chronic disease. Medi-Cal now provides health care coverage for one in three Californian’s and 43% of the state’s total diabetic population. Nearly every other health plan has chosen to cover CGM, including Covered California, Medicare, and the Medicaid programs in 30 other states, but Medi-Cal refuses to provide coverage for a technology that is clinically proven to improve blood sugar management and reduce the odds of catastrophic consequences from poor diabetes management such as hypoglycemia, amputations, and blindness. The result is that California suffers extreme economic and racial disparities in health care outcomes among our diabetic population, and this disparity is particularly acute for economically disadvantaged Californians served by Medi-Cal, who currently undergo up to 10 times as many diabetes-related amputations as their non-Medi-Cal counterparts.
- DM. DM is a chronic disease with short-and long-term health effects that prevents the proper production of and/or response to insulin, a hormone that facilitates the transfer of glucose into cells to provide energy. The two primary types of diabetes are as follows:
- Type 1 DM (Type 1) is an autoimmune disease, most commonly diagnosed during childhood/adolescence that attacks and destroys the insulin-producing cells in the pancreas. In addition to dietary modifications, treatment requires lifetime use of daily insulin injections and/or an insulin pump used to replace the patient’s impaired ability to produce insulin, and attention to diet; and,
- Type 2 DM (Type 2) is most commonly diagnosed in middle-aged or older adults, although it has been increasingly diagnosed in children and adolescents. Type 2 diabetes prevents the body from properly responding to insulin (known as insulin resistance). In some cases, people with Type 2 also do not make enough insulin. It is associated with obesity, genetics, and lifestyle patterns. Treatments for Type 2 include diet modifications, exercise, weight loss, oral medications, non-insulin injected medications, and/or insulin depending on the severity of the disease, which progresses over time, especially with inadequate treatment.
Achieving stable, healthy blood glucose levels is challenging for individuals with diabetes and has adverse health consequence in the short- and long-term. On a daily basis, people with diabetes can experience swings between very high blood glucose levels (hyperglycemia) and extremely low blood glucose levels (hypoglycemia). Changes in stress, sleep, physical activity, diet, and acute illnesses contribute to hyper-and hypoglycemic events. Hyperglycemia is exhibited through increased thirst or hunger, frequent urination, headache, and fatigue. Left untreated, particularly in Type 1, it may develop into ketoacidosis where the body develops a toxic amount of ketones (toxic acids) for energy, which can lead to coma or death. Symptoms of hypoglycemia can begin as mild (e.g., anxiety, sleepiness, and tremors) and, if left untreated, escalate to serious health events such as cognitive dysfunction, seizures, coma, and death.
Some patients (between 20% and 40% of Type 1 patients and 10% of Type 2 patients) are diagnosed with hypoglycemia unawareness, a condition in which individuals are unable to sense dangerously low blood sugar early enough to reverse it, which puts them at high risk for severe hypoglycemic events requiring hospitalization. People with this condition are required to perform more frequent blood glucose testing than those who can feel their blood glucose levels dropping. A 2015 study estimated that, among people with hypoglycemic unawareness, 2.4 to 8.1 hospitalizations occur annually among Type 1 patients, and 2.1 to 5.9 hospitalizations per year among Type 2 patients. Hypoglycemia unawareness occurs more frequently among those with a longer duration of diabetes, who are insulin dependent, and/or have a history of hypoglycemic events.
Long-term, time spent in hyperglycemia and frequency and severity of hyper- and hypoglycemia over a lifetime are associated with serious morbidity and mortality outcomes. In the United States, diabetes is the leading cause of blindness, amputations, and kidney failure, and a key contributor to stroke, heart disease, dental disease, nerve damage, and premature death due to suboptimal blood sugar control. In the long term, uncontrolled gestational diabetes puts pregnant women and their infants at higher risk of developing Type 2 later in life. Although people with diabetes may not avoid all associated comorbidities, tightly controlled blood glucose over time may prevent, delay, or ameliorate some comorbidities.
- Monitoring of blood glucose. Managing diabetes requires checking blood glucose levels through lab tests (HbA1c periodically ordered by health care providers) and daily patient self-monitoring blood glucose (SMBG), also known as a finger stick. HbA1c indicates a patient’s average glucose level over the last three months. The lab results are used by health care providers to inform the patient’s diabetes management plan. Patients perform SMBG tests one to 10 times/day to obtain “snapshot” glucose readings to help them adjust their insulin, diet, physical activity, or oral medication throughout the day and night. More frequent testing is required for insulin-dependent patients and those who have uncontrolled blood sugars, including hypoglycemia and hyperglycemia. SMBG requires the patient to prick the skin (commonly the finger for the most accurate reading) for a drop of blood, which is applied to a test strip. The strip is inserted into a handheld blood glucose monitor (glucometer) which displays a reading for the current glucose level.
In addition to HbA1c lab tests and SMBG, patients and providers may also use CGMs to help manage diabetes. Three manufacturers produce federal Food and Drug Administration-approved CGMs in the U.S. (i.e., Abbott, Dexcom, and Medtronic). These waterproof monitors, also called continuous interstitial glucose monitors, use a thin plastic catheter inserted into the subcutaneous skin (fat layer) just under the skin of the arm, back, or trunk to measure the amount of glucose in the fluid around the cells, called interstitial fluid.
CGMs may be categorized as retrospective or in real-time based on how often and by whom the glucose level readings are reviewed. Under the retrospective (professional) scenario, a health care provider asks the patient to wear the CGM for 72 hours up to one week to record glucose measurements every five to 15 minutes. The patient does not see the CGM glucose levels while wearing the device. The patient returns to the health care provider, who downloads and analyzes the retrospective data for patterns in glucose control. The provider can use this retrospective data to see when hyper- and hypoglycemia events undetected by SMBG are occurring, and to understand why a patient’s HbA1c remains uncontrolled even if SMGB results appear controlled.
Under the real-time use scenario, CGMs are worn by the patient to actively and consistently monitor glucose throughout the day and night. The patients are able to see the CGM glucose levels on their receivers (or smart phones) as the measurements are taken throughout the day and night. They also have the option to set an alarm to alert them when glucose levels go too high or too low. For real-time use, patients must move the sensor to a different place on the body at least once per week. As with data collected from a retrospective CGM, the patient and the provider can also review the detailed data to better understand the user’s glucose level patterns over time and adjust the treatment regimen accordingly.
- DHCS COVERAGE POLICY ON CGM. DHCS indicates CGMs are a covered benefit in CCS and the Genetically Handicapped Persons Program, subject to the patient and their treating specialist meeting specified criteria outlined in DHCS policy letters. For Medi-Cal, DHCS indicates CGM are a non-covered benefit, meaning that a Medi-Cal beneficiary who is over the age of 21 can obtain one with a treatment authorization request override that indicates medical necessity. For individuals under the age of 21, DHCS indicates the beneficiary may be able to obtain a CGM under the federal Early and Periodic Screening, Diagnostic, and Treatment (EPSDT), subject to prior authorization in Medi-Cal and under CCS (the medical necessity standard under EPSDT for Medi-Cal is broader for children than the adult medical necessity standard in Medi-Cal). DHCS indicates it does not have rebate contracts with CGM manufacturers.
- SUPPORT. The American Diabetes Association (ADA) writes that it supports making CGMs a Medi-Cal covered benefit because the alarm function of these monitors alerts diabetes patients when their blood levels go dangerously high or dangerously low in a way that traditional, finger stick measurement cannot. Traditional finger stick measurement only shows a snapshot of blood glucose at that moment but does not warn of rapidly rising or falling levels, which is necessary for the patient to make informed, effective decisions in managing their disease. The ADA writes that CGMs can reduce short-term costs to the Medi-Cal program by reducing severe hypoglycemic events in high-risk populations, and most states’ Medicaid program cover CGMs because they improve diabetes control and help prevent greater costs associated with hospitalizations and treatment complications.
The California Chapter for the American Association of Clinical Endocrinologists (CA-AACE) is a professional community of physicians specializing in endocrinology, diabetes, and metabolism, committed to enhancing the ability of its members to provide the highest quality of patient care. CA-AACE supports making CGMs a Medi-Cal covered benefit because the technology is medically necessary to treat certain patients with diabetes. CGMs have been shown in medical literature to improve blood glucose control and limit time spent with low blood sugars in adult patients with Type 1 diabetes. A common obstacle faced by people treated for diabetes is hypoglycemia, which occurs when blood sugar levels fall below a threshold. If not treated immediately, hypoglycemia can necessitate emergency medical treatment. Among diabetic patients receiving insulin, approximately 31% of severe hypoglycemic events require emergency services in the form of ambulance transport, emergency department visits, and hospitalizations.
Western Center on Law & Poverty (WCLP) writes in support that, although Medi-Cal covers all medically necessary services, including CGMs, legal aid advocates cite the need for this bill. WCLP states that advocates report cases of Medi-Cal managed care plans denying clients’ request for CGM, which can result in a lengthy appeal process where the plan’s decision is ultimately reversed but the client went months without the needed CGM.
- PREVIOUS LEGISLATION. AB 447 (Gray) of 2017 was identical to this bill. Governor Brown vetoed AB 447 and AB 391 (Chiu) in a combined veto message, stating DHCS has considerable administrative authority to make changes to benefits based upon new medical evidence and clinical guidelines, and that these statutory changes are unnecessary.
REGISTERED SUPPORT / OPPOSITION:
Support
Advanced Medical Technology Association
American Association of Diabetes Educators
American Congress of Obstetricians & Gynecologists - District IX
American Diabetes Association
Biocom
California Association of Health Services at Home
California Chapter for the American Association of Clinical Endocrinologists
California Coordinating Body of the American Association of Diabetes Educators
California Life Sciences Association
California School Employees Association
Diabetes Patient Advocacy Coalition
Western Center on Law & Poverty
County Health Executives Association of California
Dexcom, Inc.
Opposition
None on file.
Analysis Prepared by: Scott Bain / HEALTH / (916) 319-2097
Bill Author
Bill Co-Author(s):